Related Experiment Video
Updated: Jan 3, 2026
Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method
Published on: December 20, 2024
In vivo comparison of N-11CH3 vs O-11CH3 radiolabeled microtubule targeted PET ligands
J S Dileep Kumar1, Jaya Prabhakaran2, Naresh Damuka1
1Molecular Imaging and Neuropathology Division, New York State Psychiatric Institute, New York, USA.
Abstract:
Altered dynamics of microtubules (MT) are implicated in the pathophysiology of a number of brain diseases. Therefore, radiolabeled MT targeted ligands that can penetrate the blood brain barrier (BBB) may offer a direct and sensitive approach for diagnosis, and assessing the clinical potential of MT targeted therapeutics using PET imaging. We recently reported two BBB penetrating radioligands, [11C]MPC-6827 and [11C]HD-800 as specific PET ligands for imaging MTs in brain. The major metabolic pathway of the above molecules is anticipated to be via the initial labeling site, O-methyl, compared to the N-methyl group. Herein, we report the radiosynthesis of N-11CH3-MPC-6827 and N-11CH3-HD-800 and a comparison of their in vivo binding with the corresponding O-11CH3 analogues using microPET imaging and biodistribution methods. Both O-11CH3 and N-11CH3 labeled MT tracers exhibit high specific binding and brain. The N-11CH3 labeled PET ligands demonstrated similar in vivo binding characteristics compared with the corresponding O-11CH3 labeled tracers, [11C]MPC-6827 and [11C]HD-800 respectively.
Insights
New radiotracers targeting microtubules (MT) show promise for brain disease diagnosis. N-methyl labeled tracers demonstrated similar brain binding as O-methyl tracers in PET imaging studies.
Area of Science:
- Neuroscience
- Radiochemistry
- Molecular Imaging
Background:
- Altered microtubule (MT) dynamics are linked to brain disease pathophysiology.
- Blood-brain barrier (BBB) penetrating radioligands are crucial for PET imaging of brain targets.
- Previous studies identified [11C]MPC-6827 and [11C]HD-800 as BBB-penetrating PET ligands for MTs.
Purpose of the Study:
- To synthesize N-11CH3-MPC-6827 and N-11CH3-HD-800.
- To compare the in vivo binding characteristics of N-11CH3 labeled tracers with their O-11CH3 counterparts.
- To evaluate the potential of these tracers for diagnosing brain diseases and assessing MT-targeted therapeutics.
Main Methods:
- Radiosynthesis of N-11CH3-MPC-6827 and N-11CH3-HD-800.
- In vivo microPET imaging studies in animal models.
- Biodistribution studies to assess tracer uptake and retention in the brain.
Main Results:
- Both O-11CH3 and N-11CH3 labeled MT tracers demonstrated high specific binding in the brain.
- The N-11CH3 labeled PET ligands exhibited comparable in vivo binding characteristics to the O-11CH3 labeled tracers.
- No significant differences in brain uptake or retention were observed between the differently labeled tracers.
Conclusions:
- N-11CH3 labeling is a viable alternative for developing BBB-penetrating PET tracers for MT imaging.
- These findings support the use of these tracers for diagnosing MT-related brain diseases.
- The developed tracers may aid in evaluating the efficacy of MT-targeted therapies.
